1-20 of 24
Shivaani Kummar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors

Anthony W. Tolcher, Joshua D. Brody, Nishanthan Rajakumaraswamy, Michelle Kuhne, Torsten Trowe, Anees M. Dauki, Shantheri Pai, Ling Han, Kai-Wen Lin, Michael Petrarca, Shivaani Kummar
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2954–2963.
https://doi.org/10.1158/1078-0432.CCR-23-2808
Published: 15 July 2024
View article titled, Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

James Nguyen, Naoko Takebe, Shivaani Kummar, Albiruni Razak, Sant P. Chawla, Suzanne George, Shreyaskumar R. Patel, Mary Louise Keohan, Sujana Movva, Geraldine O'Sullivan Coyne, Khanh Do, Lamin Juwara, Brooke Augustine, Seth M. Steinberg, Laura Kuhlmann, S. Percy Ivy, James H. Doroshow, Alice P. Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1200–1208.
https://doi.org/10.1158/1078-0432.CCR-22-2145
Published: 03 April 2023
View article titled, Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
Open the PDF for Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma in another window
Journal Articles

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T. Gibney, Howard A. Burris, Scott S. Tykodi, Osama E. Rahma, Tanguy Y. Seiwert, Kyriakos P. Papadopoulos, Mariela Blum Murphy, Haeseong Park, Amanda Hanson, Yasmin Hashambhoy-Ramsay, Lara McGrath, Ellen Hooper, Xiaoying Xiao, Heather Cohen, Martin Fan, Daniel Felitsky, Courtney Hart, Rachel McComb, Karen Brown, Ali Sepahi, Judith Jimenez, Weidong Zhang, Johan Baeck, Haley Laken, Richard Murray, Elizabeth Trehu, Christopher J. Harvey
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3695–3708.
https://doi.org/10.1158/1078-0432.CCR-21-4256
Published: 01 September 2022
View article titled, First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
Open the PDF for First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response in another window
Includes: Supplementary data
Journal Articles

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do, Jennifer Zlott, Ashley Bruns, Lawrence Rubinstein, Jared C. Foster, Lamin Juwara, Robert Meehan, Richard Piekarz, Howard Streicher, Elad Sharon, Naoko Takebe, Andrea Regier Voth, Donald Bottaro, Rene Costello, John J. Wright, James H. Doroshow, Alice P. Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 279–288.
https://doi.org/10.1158/1078-0432.CCR-21-2480
Published: 15 January 2022
View article titled, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Open the PDF for Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Michael L. Maitland, Jasgit C. Sachdev, Manish R. Sharma, Victor Moreno, Valentina Boni, Shivaani Kummar, Erica Stringer-Reasor, Nehal Lakhani, Allison R. Moreau, Dawei Xuan, Ray Li, Eric L. Powell, Amy Jackson-Fisher, Michelle Bowers, Shilpa Alekar, Xiaohua Xin, Anthony W. Tolcher, Emiliano Calvo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4511–4520.
https://doi.org/10.1158/1078-0432.CCR-20-3757
Published: 15 August 2021
View article titled, First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
Open the PDF for First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Naoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, Shivaani Kummar, Khanh Do, Ashley Bruns, Lamin Juwara, Jennifer Zlott, Larry Rubinstein, Richard Piekarz, Elad Sharon, Howard Streicher, Arjun Mittra, Sarah B. Miller, Jiuping Ji, Deborah Wilsker, Robert J. Kinders, Ralph E. Parchment, Li Chen, Ting-Chia Chang, Biswajit Das, Ganesh Mugundu, James H. Doroshow, Alice P. Chen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (14): 3834–3844.
https://doi.org/10.1158/1078-0432.CCR-21-0329
Published: 15 July 2021
View article titled, Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
Open the PDF for Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Roisin M. Connolly, Eric Laille, Ulka Vaishampayan, Vincent Chung, Karen Kelly, Afshin Dowlati, Olatunji B. Alese, R. Donald Harvey, Paul Haluska, Lillian L. Siu, Shivaani Kummar, Richard Piekarz, S. Percy Ivy, Nicole M. Anders, Melinda Downs, Ashley O'Connor, Angela Scardina, Jacqueline Saunders, Gary L. Rosner, Michael A. Carducci, Michelle A. Rudek
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5329–5337.
https://doi.org/10.1158/1078-0432.CCR-20-1412
Published: 15 October 2020
View article titled, Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Open the PDF for Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study in another window
Journal Articles

Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers

Deborah F. Wilsker, Allison M. Barrett, Angie B. Dull, Scott M. Lawrence, Melinda G. Hollingshead, Alice Chen, Shivaani Kummar, Ralph E. Parchment, James H. Doroshow, Robert J. Kinders
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (10): 3084–3095.
https://doi.org/10.1158/1078-0432.CCR-18-2523
Published: 15 May 2019
View article titled, Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers
Open the PDF for Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial

Ann M. Mohrbacher, Allen S. Yang, Susan Groshen, Shivaani Kummar, Martin E. Gutierrez, Min H. Kang, Denice Tsao-Wei, C. Patrick Reynolds, Edward M. Newman, Barry J. Maurer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (16): 4550–4555.
https://doi.org/10.1158/1078-0432.CCR-17-0234
Published: 14 August 2017
View article titled, Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
Open the PDF for Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial in another window
Includes: Supplementary data
Journal Articles

Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use

Apurva K. Srivastava, Soumya Jaganathan, Laurie Stephen, Melinda G. Hollingshead, Adam Layhee, Eric Damour, Jeevan Prasaad Govindharajulu, Jennifer Donohue, Dominic Esposito, James P. Mapes, Robert J. Kinders, Naoko Takebe, Joseph E. Tomaszewski, Shivaani Kummar, James H. Doroshow, Ralph E. Parchment
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 1000–1010.
https://doi.org/10.1158/1078-0432.CCR-14-3156
Published: 14 February 2016
View article titled, Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use
Open the PDF for Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use in another window
Includes: Supplementary data
Journal Articles

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Shivaani Kummar, Amit M. Oza, Gini F. Fleming, Daniel M. Sullivan, David R. Gandara, Michael J. Naughton, Miguel A. Villalona-Calero, Robert J. Morgan, Jr, Peter M. Szabo, Ahrim Youn, Alice P. Chen, Jiuping Ji, Deborah E. Allen, Chih-Jian Lih, Michele G. Mehaffey, William D. Walsh, Paul M. McGregor, III, Seth M. Steinberg, P. Mickey Williams, Robert J. Kinders, Barbara A. Conley, Richard M. Simon, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1574–1582.
https://doi.org/10.1158/1078-0432.CCR-14-2565
Published: 31 March 2015
View article titled, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <em>BRCA</em>-Mutant Ovarian Cancer
Open the PDF for Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <em>BRCA</em>-Mutant Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

New, Tolerable γ-Secretase Inhibitor Takes Desmoid Down a Notch

Dennis P.M. Hughes, Shivaani Kummar, Alexander J. Lazar
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (1): 7–9.
https://doi.org/10.1158/1078-0432.CCR-14-1660
Published: 05 January 2015
View article titled, New, Tolerable γ-Secretase Inhibitor Takes Desmoid Down a Notch
Open the PDF for New, Tolerable γ-Secretase Inhibitor Takes Desmoid Down a Notch in another window
Journal Articles

Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Stephen I. Shibata, Vincent Chung, Timothy W. Synold, Jeffrey A. Longmate, A. Benjamin Suttle, Lone H. Ottesen, Heinz-Josef Lenz, Shivaani Kummar, R. Donald Harvey, Anne L. Hamilton, Bert H. O'Neil, John Sarantopoulos, Patricia LoRusso, Michelle A. Rudek, Afshin Dowlati, Daniel L. Mulkerin, Chandra P. Belani, Leena Gandhi, S. Cecilia Lau, S. Percy Ivy, Edward M. Newman
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3631–3639.
https://doi.org/10.1158/1078-0432.CCR-12-3214
Published: 30 June 2013
View article titled, Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Open the PDF for Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase 0 Trial of Oral 5-Iodo-2-Pyrimidinone-2′-Deoxyribose in Patients with Advanced Malignancies

Shivaani Kummar, Larry Anderson, Kimberly Hill, Eva Majerova, Deborah Allen, Yvonne Horneffer, S. Percy Ivy, Larry Rubinstein, Pamela Harris, James H. Doroshow, Jerry M. Collins
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1852–1857.
https://doi.org/10.1158/1078-0432.CCR-12-3118
Published: 02 April 2013
View article titled, First-in-Human Phase 0 Trial of Oral 5-Iodo-2-Pyrimidinone-2′-Deoxyribose in Patients with Advanced Malignancies
Open the PDF for First-in-Human Phase 0 Trial of Oral 5-Iodo-2-Pyrimidinone-2′-Deoxyribose in Patients with Advanced Malignancies in another window
Journal Articles

A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors

Arun Rajan, Corey A. Carter, Ronan J. Kelly, Martin Gutierrez, Shivaani Kummar, Eva Szabo, Mary Ann Yancey, Jiuping Ji, Baskar Mannargudi, Sukyung Woo, Shawn Spencer, William Douglas Figg, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (8): 2344–2351.
https://doi.org/10.1158/1078-0432.CCR-11-2425
Published: 16 April 2012
View article titled, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Open the PDF for A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

Cody J. Peer, Tristan M. Sissung, AeRang Kim, Lokesh Jain, Sukyung Woo, Erin R. Gardner, C. Tyler Kirkland, Sarah M. Troutman, Bevin C. English, Emily D. Richardson, Joel Federspiel, David Venzon, William Dahut, Elise Kohn, Shivaani Kummar, Robert Yarchoan, Giuseppe Giaccone, Brigitte Widemann, William D. Figg
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (7): 2099–2107.
https://doi.org/10.1158/1078-0432.CCR-11-2484
Published: 01 April 2012
View article titled, Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
Open the PDF for Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Shivaani Kummar, Jiuping Ji, Robert Morgan, Heinz-Josef Lenz, Shannon L. Puhalla, Chandra P. Belani, David R. Gandara, Deborah Allen, Brian Kiesel, Jan H. Beumer, Edward M. Newman, Larry Rubinstein, Alice Chen, Yiping Zhang, Lihua Wang, Robert J. Kinders, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1726–1734.
https://doi.org/10.1158/1078-0432.CCR-11-2821
Published: 14 March 2012
View article titled, A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Open the PDF for A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

Arun Rajan, Ronan J. Kelly, Jane B. Trepel, Yeong Sang Kim, Sylvia V. Alarcon, Shivaani Kummar, Martin Gutierrez, Sonja Crandon, Wadih M. Zein, Lokesh Jain, Baskar Mannargudi, William D. Figg, Brett E. Houk, Michael Shnaidman, Nicoletta Brega, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6831–6839.
https://doi.org/10.1158/1078-0432.CCR-11-0821
Published: 31 October 2011
View article titled, A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas
Open the PDF for A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas in another window
Includes: Supplementary data
Journal Articles

Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer

Athanassios Argiris, Austin G. Duffy, Shivaani Kummar, Nicole L. Simone, Yoshio Arai, Seungwon W. Kim, Susan F. Rudy, Vishnu R. Kannabiran, Xinping Yang, Minyoung Jang, Zhong Chen, Nanette Suksta, Theresa Cooley-Zgela, Susmita G. Ramanand, Aarif Ahsan, Mukesh K. Nyati, John J. Wright, Carter Van Waes
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5755–5764.
https://doi.org/10.1158/1078-0432.CCR-11-0861
Published: 01 September 2011
View article titled, Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
Open the PDF for Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors

Shivaani Kummar, Mark Raffeld, Lamin Juwara, Yvonne Horneffer, Agnes Strassberger, Deborah Allen, Seth M. Steinberg, Annamaria Rapisarda, Shawn D. Spencer, William D. Figg, Xiaohong Chen, Ismail Baris Turkbey, Peter Choyke, Anthony J. Murgo, James H. Doroshow, Giovanni Melillo
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5123–5131.
https://doi.org/10.1158/1078-0432.CCR-11-0682
Published: 31 July 2011
View article titled, Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors
Open the PDF for Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors in another window
Includes: Supplementary data